Canagliflozin → Fungal infection — Audit-grade candidate (class scan)

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Canagliflozin → Fungal infection — Audit-grade candidate (class scan)

Drug: canagliflozin · AE: Fungal infection

Discovered via class scan of SGLT2 inhibitors. PRR = 31.49, n = 1423 cases.

Disproportionality

PRR: 31.488676573879786
Yates χ²: n/a
Cases (case-drug + AE): n = 1423
Verdict: PASSES_ALL_GATES — PRR=31.49 (95% CI 29.91–33.16), n=1423 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: 620f50db169e8489a08f777a7b4c087b2ed29812